TuHURA Biosciences is a phase 3 clinical stage immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapies. Its lead product IFx-2.0 is an innate immune agonist in a Phase 3 trial combined with Keytruda for Merkel cell carcinoma. The company also holds TBS-2025, a VISTA-inhibiting monoclonal antibody acquired via Kineta for AML treatment, and a Delta Opioid Receptor ADC technology targeting myeloid-derived suppressor cells.
expected 2026-12-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134950 | EDGAR | 90K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047921 | EDGAR | 101K words |
| 2024-10-07 | 2024-06-30 | 0000950170-24-113321 | EDGAR | 67K words |
| 2023-09-18 | 2023-06-30 | 0000950170-23-048588 | EDGAR | 72K words |
| 2022-09-27 | 2022-06-30 | 0000950170-22-018865 | EDGAR | — |
| 2021-09-28 | 2021-06-30 | 0001564590-21-049235 | EDGAR | — |
| 2020-09-18 | 2020-06-30 | 0001564590-20-044019 | EDGAR | — |
| 2019-09-09 | 2019-06-30 | 0001213900-19-017497 | EDGAR | — |
| 2018-09-24 | 2018-06-30 | 0001213900-18-012876 | EDGAR | — |
| 2017-09-27 | 2017-06-30 | 0001213900-17-010055 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001193125-26-350451 | EDGAR | 19K words |
| 2025-11-14 | 2025-09-30 | 0001193125-25-281539 | EDGAR | 26K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108972 | EDGAR | 23K words |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072745 | EDGAR | 22K words |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127199 | EDGAR | 18K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059694 | EDGAR | 22K words |
| 2024-02-14 | 2023-12-31 | 0000950170-24-015204 | EDGAR | 20K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062915 | EDGAR | 18K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020854 | EDGAR | 22K words |
| 2023-02-14 | 2022-12-31 | 0000950170-23-002805 | EDGAR | 22K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023988 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0000950170-22-009809 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-24 | 0001193125-26-401140 | EDGAR | 1K words |
| 2026-09-17 | 0001193125-26-394473 | EDGAR | 1K words |
| 2026-09-16 | 0001193125-26-393206 | EDGAR | 11K words |
| 2026-09-04 | 0001193125-26-383797 | EDGAR | 1K words |
| 2026-08-21 | 0001193125-26-361272 | EDGAR | 1K words |
| 2026-08-19 | 0001193125-26-357087 | EDGAR | 2K words |
| 2026-08-14 | 0001193125-26-350425 | EDGAR | 1K words |
| 2026-08-13 | 0001193125-26-349540 | EDGAR | 1K words |
| 2026-07-29 | 0001193125-26-324174 | EDGAR | 1K words |
| 2026-04-01 | 0001193125-26-135766 | EDGAR | 1K words |
342 total filings indexed. 310 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001498382 |
| Ticker | HURA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.tuhurabio.com |
| Listed | 2024-10-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/HURA (~200 tokens, structured JSON with cryptographic provenance)